1173435-26-1Relevant articles and documents
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists
Hartz, Richard A.,Ahuja, Vijay T.,Arvanitis, Argyrios G.,Rafalski, Maria,Yue, Eddy W.,Denhart, Derek J.,Schmitz, William D.,Ditta, Jonathan L.,Deskus, Jeffrey A.,Brenner, Allison B.,Hobbs, Frank W.,Payne, Joseph,Lelas, Snjezana,Li, Yu-Wen,Molski, Thaddeus F.,Mattson, Gail K.,Peng, Yong,Wong, Harvey,Grace, James E.,Lentz, Kimberley A.,Qian-Cutrone, Jingfang,Zhuo, Xiaoliang,Shu, Yue-Zhong,Lodge, Nicholas J.,Zaczek, Robert,Combs, Andrew P.,Olson, Richard E.,Bronson, Joanne J.,Mattson, Ronald J.,Macor, John E.
experimental part, p. 4173 - 4191 (2010/02/17)
Evidence suggests that corticotropin-releasing factor-1 (CRF1) receptor antagonistsmay offer therapeutic potential for the treatment of diseases associated with elevated levels of CRF such as anxiety and depression. A pyrazinone-based chemotype